The continued acceleration in implants over the last several years is certainly not justified by the share price.
They're not selling a drug, it's a heart pump which requires a lot of work building the foundation in training surgeons, establishing implant centres etc. Although in the end it could be just as lucrative as any drug.
Because of all the upfront work required, things happened slower than most expected. Which may partly explain the current share price, an overreaction to the downside.
I guess on the bright side any company that wants to compete will have to retrace the same footsteps.
VCR Price at posting:
10.0¢ Sentiment: LT Buy Disclosure: Held
